Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group Inc (MDXG) delivers innovative regenerative biologics for advanced wound care and surgical recovery, leveraging human placental tissue allografts and proprietary processing technologies. This news hub provides stakeholders with verified updates about the company's operational milestones, clinical advancements, and regulatory engagements.
Investors and medical professionals will find a comprehensive repository of press releases detailing financial results, product launches, and research developments. Key coverage areas span quarterly earnings disclosures, FDA regulatory updates, strategic partnership announcements, and clinical study publications validating MDXG's biomaterial solutions.
All content is curated to maintain factual accuracy and timeliness, with direct links to official SEC filings and peer-reviewed research. The resource emphasizes MDXG's patented Purion® processing methodology and its applications in chronic wound management across healthcare settings.
Bookmark this page for streamlined access to MiMedx's latest developments in therapeutic biologics, including innovations in xenograft solutions and digital platforms enhancing clinical workflow efficiency. Regular updates ensure informed tracking of the company's progress in regenerative medicine markets.
Prescience Point Capital Management has raised the price target for MiMedx Group Inc. (MDXG) to $31 per share. Prescience, a major shareholder with 6.5% ownership, highlights its analysis of the Amniofix injectable product currently in Phase 2b trials for knee osteoarthritis and Phase 3 for plantar fasciitis. Findings suggest Amniofix could be a revolutionary treatment, with potential for billions in annual sales. The firm anticipates FDA approval for knee OA and other indications, indicating substantial undervalue in current share prices.
MARIETTA, Ga., Dec. 07, 2020 - MiMedx Group, Inc. (Nasdaq: MDXG) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 4:30 PM EST. The company, known for its advanced wound care solutions, invites institutional investors to connect with management through J.P. Morgan representatives. A live webcast can be accessed on the company's website, with a replay available post-presentation. MiMedx specializes in human placental tissue allografts and has supplied over two million allografts using its proprietary processes.
MiMedx Group, Inc. (NASDAQ: MDXG) has appointed Jack Howarth as Senior Vice President of Investor Relations. With 25 years in public relations and financial communications, plus 40 years in the medical sector, Howarth aims to enhance the company’s visibility within the financial community. CEO Timothy R. Wright emphasized the need for effective communications as MiMedx seeks to expand its market leadership in advanced wound care. Howarth previously held significant roles in various pharmaceutical firms, including Antares Pharmaceuticals and King Pharmaceuticals.
MiMedx Group has announced that CEO Timothy R. Wright and CFO Peter M. Carlson will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference happening from December 1-3, 2020. A pre-recorded presentation will be available on the company's website starting November 25, 2020, at 5:00 PM Eastern Time, and will be accessible for 45 days. MiMedx specializes in advanced wound care and therapeutic biologics, particularly using PURION technology to produce human placental tissue allografts, having supplied over 2 million allografts to date.
MiMedx Group, a leader in advanced wound care, announced its virtual 2020 Annual Meeting of Shareholders to be held on November 20, 2020, at 10:00 a.m. Eastern Time. CEO Timothy R. Wright, alongside other senior executives, will present company updates, including commercial and R&D initiatives. Shareholders must log in 15 minutes early to participate via the virtual platform. The definitive proxy statement has been filed with the SEC, and shareholders can access it through the SEC’s website or MiMedx's website.
MiMedx Group, a leader in advanced wound care, announced its upcoming presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 9:30 AM ET. CEO Timothy R. Wright and CFO Peter M. Carlson will represent the company. A live webcast will be available on the company’s website. This forum highlights MiMedx's commitment to innovation in therapeutic biologics, specifically in human placental tissue allografts, which have exceeded two million shipments to date.
MiMedx Group reported third quarter 2020 net sales of $64.3 million, a 28% decrease from $88.9 million in Q3 2019. Adjusted EBITDA reached $6.9 million, or 10.8% of net sales. The company incurred a net loss of $19.4 million, largely attributed to $12.0 million in investigation-related expenses. On a positive note, MiMedx announced its shares were relisted on Nasdaq under ticker MDXG and secured coverage for EpiFix® from the largest U.S. commercial payor, contributing to a planned salesforce expansion.
MiMedx Group, Inc. (NASDAQ: MDXG) announced its participation in the Symposium on Advanced Wound Care Fall, taking place from November 4-6. The company will showcase its new EpiCord Expandable allograft, which can expand to twice its size, enhancing treatment for chronic wounds. Experts will discuss the quality of clinical trials in wound care, emphasizing bias in study designs. MiMedx has processed over two million allografts and aims to improve patient outcomes through innovative products and scientific research.
MiMedx Group, Inc. (OTC PINK: MDXG) announced that its common stock will begin trading on The Nasdaq Stock Market from November 4, 2020. This move marks a significant milestone for the company, which specializes in advanced wound care and therapeutic biologics. MiMedx is recognized for its development and distribution of human placental tissue allografts using its proprietary PURION® process. The company has successfully supplied over two million allografts to the healthcare sector.
MiMedx Group (OTC PINK: MDXG) filed a definitive proxy statement with the SEC for its 2020 Annual Meeting of Shareholders, set for November 20, 2020, at 10:00 a.m. ET. Due to COVID-19 concerns, the meeting will be virtual. Shareholders as of October 7, 2020, can participate and vote. The proxy statement and voting information are being mailed out, with accessible copies on the SEC and MiMedx websites. MiMedx specializes in advanced wound care through human placental tissue allografts, having supplied over 1.9 million allografts to date.
FAQ
What is the current stock price of Mimedx Group (MDXG)?
What is the market cap of Mimedx Group (MDXG)?
